nodes	percent_of_prediction	percent_of_DWPC	metapath
Nateglinide—SLC16A1—Methotrexate—lymphatic system cancer	0.209	0.24	CbGbCtD
Nateglinide—CYP3A5—Teniposide—lymphatic system cancer	0.103	0.118	CbGbCtD
Nateglinide—ABCC4—Methotrexate—lymphatic system cancer	0.101	0.115	CbGbCtD
Nateglinide—CYP2C9—Teniposide—lymphatic system cancer	0.069	0.079	CbGbCtD
Nateglinide—CYP3A7—Vincristine—lymphatic system cancer	0.066	0.0756	CbGbCtD
Nateglinide—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.066	0.0756	CbGbCtD
Nateglinide—CYP3A5—Vincristine—lymphatic system cancer	0.0495	0.0567	CbGbCtD
Nateglinide—SLC22A6—Methotrexate—lymphatic system cancer	0.0438	0.0502	CbGbCtD
Nateglinide—CYP3A4—Cytarabine—lymphatic system cancer	0.0407	0.0467	CbGbCtD
Nateglinide—CYP3A4—Teniposide—lymphatic system cancer	0.0401	0.046	CbGbCtD
Nateglinide—ALB—Methotrexate—lymphatic system cancer	0.0373	0.0427	CbGbCtD
Nateglinide—CYP3A4—Mitoxantrone—lymphatic system cancer	0.028	0.0321	CbGbCtD
Nateglinide—CYP3A4—Vincristine—lymphatic system cancer	0.0193	0.0221	CbGbCtD
Nateglinide—PPARG—Etoposide—Teniposide—lymphatic system cancer	0.00819	1	CbGdCrCtD
Nateglinide—Trauma—Bleomycin—lymphatic system cancer	0.0052	0.0436	CcSEcCtD
Nateglinide—Jaundice—Mechlorethamine—lymphatic system cancer	0.00284	0.0238	CcSEcCtD
Nateglinide—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.00247	0.0207	CcSEcCtD
Nateglinide—Hepatic enzyme increased—Mitoxantrone—lymphatic system cancer	0.00212	0.0178	CcSEcCtD
Nateglinide—Neuropathy peripheral—Teniposide—lymphatic system cancer	0.00211	0.0177	CcSEcCtD
Nateglinide—Sweating increased—Fludarabine—lymphatic system cancer	0.00206	0.0173	CcSEcCtD
Nateglinide—Sweating—Teniposide—lymphatic system cancer	0.00206	0.0173	CcSEcCtD
Nateglinide—Bronchitis—Fludarabine—lymphatic system cancer	0.00204	0.0171	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Fludarabine—lymphatic system cancer	0.00197	0.0165	CcSEcCtD
Nateglinide—Injury—Bleomycin—lymphatic system cancer	0.00196	0.0164	CcSEcCtD
Nateglinide—Urine output increased—Vincristine—lymphatic system cancer	0.00187	0.0156	CcSEcCtD
Nateglinide—Neuropathy peripheral—Fludarabine—lymphatic system cancer	0.00185	0.0155	CcSEcCtD
Nateglinide—Injury—Carmustine—lymphatic system cancer	0.00171	0.0143	CcSEcCtD
Nateglinide—Polyuria—Vincristine—lymphatic system cancer	0.00171	0.0143	CcSEcCtD
Nateglinide—Erythema multiforme—Fludarabine—lymphatic system cancer	0.0016	0.0134	CcSEcCtD
Nateglinide—Malnutrition—Fludarabine—lymphatic system cancer	0.00148	0.0124	CcSEcCtD
Nateglinide—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00137	0.0115	CcSEcCtD
Nateglinide—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00133	0.0111	CcSEcCtD
Nateglinide—Pruritus—Mechlorethamine—lymphatic system cancer	0.00132	0.011	CcSEcCtD
Nateglinide—Cough—Fludarabine—lymphatic system cancer	0.00129	0.0108	CcSEcCtD
Nateglinide—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00127	0.0107	CcSEcCtD
Nateglinide—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00123	0.0103	CcSEcCtD
Nateglinide—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00119	0.00994	CcSEcCtD
Nateglinide—Vomiting—Mechlorethamine—lymphatic system cancer	0.00118	0.00991	CcSEcCtD
Nateglinide—Rash—Mechlorethamine—lymphatic system cancer	0.00117	0.00983	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00117	0.00982	CcSEcCtD
Nateglinide—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00117	0.00982	CcSEcCtD
Nateglinide—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00116	0.00976	CcSEcCtD
Nateglinide—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00113	0.00948	CcSEcCtD
Nateglinide—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00112	0.0094	CcSEcCtD
Nateglinide—Sweating—Vincristine—lymphatic system cancer	0.00111	0.00928	CcSEcCtD
Nateglinide—Nausea—Mechlorethamine—lymphatic system cancer	0.0011	0.00926	CcSEcCtD
Nateglinide—Jaundice—Mitoxantrone—lymphatic system cancer	0.0011	0.00918	CcSEcCtD
Nateglinide—Urticaria—Teniposide—lymphatic system cancer	0.00109	0.00913	CcSEcCtD
Nateglinide—Abdominal pain—Teniposide—lymphatic system cancer	0.00108	0.00909	CcSEcCtD
Nateglinide—Sweating—Mitoxantrone—lymphatic system cancer	0.00108	0.00903	CcSEcCtD
Nateglinide—Oedema peripheral—Carmustine—lymphatic system cancer	0.00107	0.00896	CcSEcCtD
Nateglinide—Dyspepsia—Fludarabine—lymphatic system cancer	0.00106	0.00889	CcSEcCtD
Nateglinide—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.00106	0.00887	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00104	0.00872	CcSEcCtD
Nateglinide—Fatigue—Fludarabine—lymphatic system cancer	0.00104	0.00871	CcSEcCtD
Nateglinide—Hypersensitivity—Teniposide—lymphatic system cancer	0.00101	0.00847	CcSEcCtD
Nateglinide—Asthenia—Teniposide—lymphatic system cancer	0.000984	0.00825	CcSEcCtD
Nateglinide—Pruritus—Teniposide—lymphatic system cancer	0.00097	0.00813	CcSEcCtD
Nateglinide—Malnutrition—Carmustine—lymphatic system cancer	0.000945	0.00792	CcSEcCtD
Nateglinide—Cough—Bleomycin—lymphatic system cancer	0.000945	0.00792	CcSEcCtD
Nateglinide—Diarrhoea—Teniposide—lymphatic system cancer	0.000938	0.00786	CcSEcCtD
Nateglinide—Back pain—Carmustine—lymphatic system cancer	0.000914	0.00766	CcSEcCtD
Nateglinide—Urine output increased—Methotrexate—lymphatic system cancer	0.000905	0.00759	CcSEcCtD
Nateglinide—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000888	0.00744	CcSEcCtD
Nateglinide—Tremor—Carmustine—lymphatic system cancer	0.000885	0.00742	CcSEcCtD
Nateglinide—Back pain—Vincristine—lymphatic system cancer	0.000873	0.00731	CcSEcCtD
Nateglinide—Vomiting—Teniposide—lymphatic system cancer	0.000872	0.00731	CcSEcCtD
Nateglinide—Asthenia—Fludarabine—lymphatic system cancer	0.000865	0.00725	CcSEcCtD
Nateglinide—Rash—Teniposide—lymphatic system cancer	0.000864	0.00725	CcSEcCtD
Nateglinide—Dermatitis—Teniposide—lymphatic system cancer	0.000864	0.00724	CcSEcCtD
Nateglinide—Pruritus—Fludarabine—lymphatic system cancer	0.000853	0.00715	CcSEcCtD
Nateglinide—Back pain—Mitoxantrone—lymphatic system cancer	0.00085	0.00712	CcSEcCtD
Nateglinide—Polyuria—Methotrexate—lymphatic system cancer	0.000828	0.00694	CcSEcCtD
Nateglinide—Diarrhoea—Fludarabine—lymphatic system cancer	0.000824	0.00691	CcSEcCtD
Nateglinide—Nausea—Teniposide—lymphatic system cancer	0.000814	0.00683	CcSEcCtD
Nateglinide—Cough—Mitoxantrone—lymphatic system cancer	0.000767	0.00643	CcSEcCtD
Nateglinide—Vomiting—Fludarabine—lymphatic system cancer	0.000766	0.00642	CcSEcCtD
Nateglinide—Rash—Fludarabine—lymphatic system cancer	0.00076	0.00637	CcSEcCtD
Nateglinide—Dermatitis—Fludarabine—lymphatic system cancer	0.000759	0.00636	CcSEcCtD
Nateglinide—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000727	0.00609	CcSEcCtD
Nateglinide—Nausea—Fludarabine—lymphatic system cancer	0.000716	0.006	CcSEcCtD
Nateglinide—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000712	0.00597	CcSEcCtD
Nateglinide—Urticaria—Bleomycin—lymphatic system cancer	0.000702	0.00588	CcSEcCtD
Nateglinide—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000693	0.00581	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000666	0.00558	CcSEcCtD
Nateglinide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000651	0.00546	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000636	0.00533	CcSEcCtD
Nateglinide—Fatigue—Vincristine—lymphatic system cancer	0.000635	0.00532	CcSEcCtD
Nateglinide—Asthenia—Bleomycin—lymphatic system cancer	0.000634	0.00531	CcSEcCtD
Nateglinide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000631	0.00529	CcSEcCtD
Nateglinide—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000631	0.00529	CcSEcCtD
Nateglinide—Pruritus—Bleomycin—lymphatic system cancer	0.000625	0.00524	CcSEcCtD
Nateglinide—Fatigue—Mitoxantrone—lymphatic system cancer	0.000618	0.00518	CcSEcCtD
Nateglinide—Abdominal pain—Carmustine—lymphatic system cancer	0.00061	0.00511	CcSEcCtD
Nateglinide—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000602	0.00505	CcSEcCtD
Nateglinide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000586	0.00491	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000584	0.00489	CcSEcCtD
Nateglinide—Abdominal pain—Vincristine—lymphatic system cancer	0.000582	0.00488	CcSEcCtD
Nateglinide—Urticaria—Mitoxantrone—lymphatic system cancer	0.00057	0.00477	CcSEcCtD
Nateglinide—Hypersensitivity—Carmustine—lymphatic system cancer	0.000568	0.00476	CcSEcCtD
Nateglinide—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000567	0.00475	CcSEcCtD
Nateglinide—Vomiting—Bleomycin—lymphatic system cancer	0.000562	0.00471	CcSEcCtD
Nateglinide—Rash—Bleomycin—lymphatic system cancer	0.000557	0.00467	CcSEcCtD
Nateglinide—Dermatitis—Bleomycin—lymphatic system cancer	0.000557	0.00467	CcSEcCtD
Nateglinide—Asthenia—Carmustine—lymphatic system cancer	0.000553	0.00464	CcSEcCtD
Nateglinide—Hypersensitivity—Vincristine—lymphatic system cancer	0.000542	0.00455	CcSEcCtD
Nateglinide—Sweating—Methotrexate—lymphatic system cancer	0.000537	0.0045	CcSEcCtD
Nateglinide—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00053	0.00444	CcSEcCtD
Nateglinide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000528	0.00443	CcSEcCtD
Nateglinide—Asthenia—Vincristine—lymphatic system cancer	0.000528	0.00443	CcSEcCtD
Nateglinide—Diarrhoea—Carmustine—lymphatic system cancer	0.000528	0.00442	CcSEcCtD
Nateglinide—Nausea—Bleomycin—lymphatic system cancer	0.000525	0.0044	CcSEcCtD
Nateglinide—Asthenia—Mitoxantrone—lymphatic system cancer	0.000514	0.00431	CcSEcCtD
Nateglinide—Dizziness—Carmustine—lymphatic system cancer	0.00051	0.00427	CcSEcCtD
Nateglinide—Diarrhoea—Vincristine—lymphatic system cancer	0.000504	0.00422	CcSEcCtD
Nateglinide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000491	0.00411	CcSEcCtD
Nateglinide—Vomiting—Carmustine—lymphatic system cancer	0.00049	0.00411	CcSEcCtD
Nateglinide—Dizziness—Vincristine—lymphatic system cancer	0.000487	0.00408	CcSEcCtD
Nateglinide—Rash—Carmustine—lymphatic system cancer	0.000486	0.00408	CcSEcCtD
Nateglinide—Dermatitis—Carmustine—lymphatic system cancer	0.000486	0.00407	CcSEcCtD
Nateglinide—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000475	0.00398	CcSEcCtD
Nateglinide—Vomiting—Vincristine—lymphatic system cancer	0.000468	0.00392	CcSEcCtD
Nateglinide—Rash—Vincristine—lymphatic system cancer	0.000464	0.00389	CcSEcCtD
Nateglinide—Dermatitis—Vincristine—lymphatic system cancer	0.000464	0.00389	CcSEcCtD
Nateglinide—Nausea—Carmustine—lymphatic system cancer	0.000458	0.00384	CcSEcCtD
Nateglinide—Vomiting—Mitoxantrone—lymphatic system cancer	0.000456	0.00382	CcSEcCtD
Nateglinide—Immune system disorder—Methotrexate—lymphatic system cancer	0.000454	0.00381	CcSEcCtD
Nateglinide—Rash—Mitoxantrone—lymphatic system cancer	0.000452	0.00379	CcSEcCtD
Nateglinide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000452	0.00379	CcSEcCtD
Nateglinide—Malnutrition—Methotrexate—lymphatic system cancer	0.000438	0.00367	CcSEcCtD
Nateglinide—Nausea—Vincristine—lymphatic system cancer	0.000437	0.00367	CcSEcCtD
Nateglinide—Nausea—Mitoxantrone—lymphatic system cancer	0.000426	0.00357	CcSEcCtD
Nateglinide—Back pain—Methotrexate—lymphatic system cancer	0.000423	0.00355	CcSEcCtD
Nateglinide—Cough—Methotrexate—lymphatic system cancer	0.000382	0.0032	CcSEcCtD
Nateglinide—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000345	0.00289	CcSEcCtD
Nateglinide—Dyspepsia—Methotrexate—lymphatic system cancer	0.000314	0.00264	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000308	0.00259	CcSEcCtD
Nateglinide—Fatigue—Methotrexate—lymphatic system cancer	0.000308	0.00258	CcSEcCtD
Nateglinide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000292	0.00245	CcSEcCtD
Nateglinide—Urticaria—Methotrexate—lymphatic system cancer	0.000284	0.00238	CcSEcCtD
Nateglinide—Abdominal pain—Methotrexate—lymphatic system cancer	0.000282	0.00237	CcSEcCtD
Nateglinide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000263	0.00221	CcSEcCtD
Nateglinide—Asthenia—Methotrexate—lymphatic system cancer	0.000256	0.00215	CcSEcCtD
Nateglinide—Pruritus—Methotrexate—lymphatic system cancer	0.000253	0.00212	CcSEcCtD
Nateglinide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000244	0.00205	CcSEcCtD
Nateglinide—Dizziness—Methotrexate—lymphatic system cancer	0.000236	0.00198	CcSEcCtD
Nateglinide—Vomiting—Methotrexate—lymphatic system cancer	0.000227	0.0019	CcSEcCtD
Nateglinide—Rash—Methotrexate—lymphatic system cancer	0.000225	0.00189	CcSEcCtD
Nateglinide—Dermatitis—Methotrexate—lymphatic system cancer	0.000225	0.00189	CcSEcCtD
Nateglinide—Nausea—Methotrexate—lymphatic system cancer	0.000212	0.00178	CcSEcCtD
